Levetiracetam
Product Images NDC 64725-1130

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 64725-1130). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tya Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (64725 1130)

This is a prescription drug called Leveteriacetam which comes in the form of tablets. The package contains 30 tablets, and the dosage information is specified in the package insert. The tablet is manufactured by Lupin Unlimited, and repackaged by T. Ya Pharmaceuticals in Tallahassee, FL. The lot number is %00 with an expiration date of XX-XX-XX.*

FDA Label Image

Image 0 (Levetiracetamtabletscombi Figure 01)

This text provides a simple formula to calculate the total daily dose of medication based on the patient's weight and the recommended daily dose in milligrams per kilogram. The medication being used has a concentration of 100 milligrams per milliliter.*

FDA Label Image

Image 1 (Levetiracetamtabletscombi Figure 02)

This text describes a formula for calculating renal clearance (CLer), which is used to determine how well the kidneys are functioning. The formula takes into account the patient's age, weight, and serum creatinine levels. For female patients, the formula is slightly different than for males. The text also mentions that the CLer can be adjusted for body surface area (BSA).*

FDA Label Image

Image 2 (Levetiracetamtabletscombi Figure 03)

FDA Label Image

Image 3 (Levetiracetamtabletscombi Figure 04)

FDA Label Image

Image 4 (Levetiracetamtabletscombi Figure 05)

This appears to be a chart or table showing the percentage of patients in a study who received either a placebo or varying doses of the medication levetiracetam. The percentages may correspond to the number of patients who experienced certain effects or outcomes. However, without further context, it is difficult to determine the exact meaning of these percentages.*

FDA Label Image

Image 5 (Levetiracetamtabletscombi Figure 06)

FDA Label Image

Image 6 (Levetiracetamtabletscombi Figure 07)

FDA Label Image

Image 7 (Levetiracetamtabletscombi Figure 08)

This is a table showing the percentage of patients in a study who experienced certain effects with either a placebo or Levetiracetam medication. The effects are not specified and the last three columns are blank.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.